High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
Iglesias-Julián Enrique, María López-Veloso, Noelia de-la-Torre-Ferrera, Julio Barraza-Vengoechea, Pedro David Delgado‐López, María Colazo-Burlato, Marta Ubeira-Iglesias, Miguel Montero-Baladía, Lorenzo-Martín Andrés, Javier Minguito-de-la-Iglesia, Juan Pablo García-Muñoz, Rodrigo Sanllorente-Sebastián, Blanca Vicente-González, Ana Alemán-Alemán, Luís Buzón
Topics & Concepts
MedicineARDSAnakinraTocilizumabInternal medicineRetrospective cohort studyCohortCytokine stormInterquartile rangeCytokine release syndromeAnesthesiaLungCoronavirus disease 2019 (COVID-19)Infectious disease (medical specialty)DiseaseCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Autoimmune and Inflammatory Disorders Research